Male Breast Cancer Completed Phase 1 Trials for Ganetespib (DB12047)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02060253Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast CancerTreatment